5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.

Source: Barron's.

Let's start with ACADIA. The biotech soared after receiving an expedited review path from the FDA for its promising treatment of Parkinson's-related hallucinations. Investors will still have to be patient, as the application for reviewing pimavanserin won't happen until late next year. However, that's still far sooner than many were expecting.

VirnetX Holdings moved higher after the European Patent Office added a patent for third-party VPN certification to the company's already impressive portfolio of intellectual capital. After a disappointing ruling earlier this month in VirnetX's patent-infringement battle, it's good to see news that breaks the company's way.

The Active Network -- the leader in online registrations for triathlons, marathons, and other endurance events -- laced up its shoes and began running uphill after expanding its relationship with Ironman. A new three-year deal will build on Active's services through nearly 190 endurance events across five different brands.

Exelixis presented encouraging preclinical data on its lead compound's effectiveness in combating cancer tumors that have metastasized to the bone. In a presentation at the annual American Association for Cancer Research meeting, a poster revealed that treatment of tumor-bearing animals on cabozantinib resulted in inhibition of tumor growth.

Shares of magicJack VocalTec soared 12% a week earlier after posting its first annual operating profit since 1996. The rally continued this week, and it may be telephony pioneer itself ready to step up as a buyer. Bloomberg reported this week that magicJack's CEO has suggested expanding the company's stock-buyback program earlier this month.